Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of disulfide compound in preparation of medicines, FBP enzyme inhibitor, and medicine for preventing and/or treating diabetes

A technology of disulfide compounds and compounds, applied in the fields of medicinal chemistry and pharmacotherapeutics, can solve problems such as poor pharmacokinetic properties and difficulty in developing inhibitors, and achieve excellent gluconeogenesis inhibition and hypoglycemic efficacy and cost The effect of low cost and simple preparation process

Active Publication Date: 2020-03-24
HUAZHONG NORMAL UNIV +1
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Substrate binding sites are difficult to develop inhibitors due to their naturally hydrophilic properties; aniline quinazolines and quinazoline derivatives have been reported to bind to subunit interface sites, but due to poor pharmacokinetic properties or other disadvantages , no reports of in vivo efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of disulfide compound in preparation of medicines, FBP enzyme inhibitor, and medicine for preventing and/or treating diabetes
  • Application of disulfide compound in preparation of medicines, FBP enzyme inhibitor, and medicine for preventing and/or treating diabetes
  • Application of disulfide compound in preparation of medicines, FBP enzyme inhibitor, and medicine for preventing and/or treating diabetes

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach 1

[0038] In formula (X), R a and R b each independently selected from substituted or unsubstituted C 1-30 Alkyl, substituted or unsubstituted C 3-20 Cycloalkyl, substituted or unsubstituted C 6-20 Aryl and substituted or unsubstituted C 2-20 A heteroaryl group containing at least one heteroatom selected from S, O and N in the heteroaryl group;

[0039] R a and R b The optional substituents in each independently selected from C 1-6 Alkyl, phenyl, C 1-6 Carboxyl, halogen, amino, C 1-6 Alkoxy, nitro, hydroxyl, C substituted by 1-3 halogen 1-6 at least one of the alkyl groups.

[0040] In the present invention, unless otherwise specified, "C 1-30 "Alkyl" means an alkyl group with a total number of carbon atoms of 1-30, including straight-chain alkyl groups and branched-chain alkyl groups, for example, the total number of carbon atoms can be 1, 2, 3, 4, 5, 6, 7, 8, 9 , 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 straight chain alkyl,...

specific Embodiment approach 2

[0047] In formula (X), R a and R b each independently selected from substituted or unsubstituted C 1-30 Alkyl, substituted or unsubstituted C 3-20 Cycloalkyl, substituted or unsubstituted C 6-20 Aryl, substituted or unsubstituted C 2-20 The heteroaryl group and the group shown in formula (Y), and R a and R b At least one of them is a group represented by formula (Y);

[0048] In the group represented by the formula (Y), R 1 and R 2 each independently selected from substituted or unsubstituted C 1-20 Alkyl, substituted or unsubstituted C 6-20 Aryl, or R 1 and R 2 Together with the same N atom to which it is attached, a substituted or unsubstituted ring A group is formed;

[0049] The ring A group is selected from saturated monocyclic groups containing at least 1 N atom, unsaturated monocyclic groups containing at least 1 N atom, saturated bicyclic bridged ring groups containing at least 1 N atom, containing at least 1 An unsaturated bicyclic bridging ring group wit...

specific Embodiment approach 3

[0052] The compound shown in the formula (X) is a compound shown in the formula (I),

[0053]

[0054] Among them, in formula (I), R 1 and R 2 each independently selected from substituted or unsubstituted C 1-20 Alkyl, substituted or unsubstituted C 6-20 Aryl, or R 1 and R 2 Together with the same N atom to which it is attached, a substituted or unsubstituted ring A group is formed;

[0055] The ring A group is selected from a saturated ring group containing at least 1 N atom, an unsaturated ring group containing at least 1 N atom, and the ring-forming atoms of the ring A group optionally contain at least one S atom and / or contain at least one O atom;

[0056] R 1 and R 2 The optional substituents in each independently selected from C 1-6 Alkyl, phenyl, C 1-6 at least one of the carboxyl groups.

[0057] Representative groups of unsubstituted ring A groups can be, for example, at least one group provided by the following substances: azetidine, tetrahydropyrrole, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicinal chemistry and pharmacotherapeutics. The invention discloses an application of a disulfide compound in preparation of medicines, an FBP enzyme inhibitorand a medicine for preventing and / or treating diabetes, and specifically provides the applications of the disulfide compound and an optical isomer or a pharmaceutically acceptable salt of the disulfide compound in preparation of at least one medicine selected from medicines with inhibition effect on fructose-1, 6-diphosphatase activity and cellular glycoisogenesis, and prevention and treatment effect on diabetes. The compounds disclosed by the invention shows excellent in-vitro and in-vivo glycoisogenesis inhibition and hypoglycemic effects, and are expected to be developed into medicines fortreating or improving diabetes.

Description

technical field [0001] The invention relates to the fields of medicinal chemistry and pharmacotherapeutics, in particular to the application of disulfide compounds in the preparation of medicines, a FBPase inhibitor and a medicament for preventing and / or treating diabetes. Background technique [0002] In recent years, with the development of society and the improvement of residents' living standards, the incidence and prevalence of diabetes have increased year by year, seriously threatening people's health. [0003] According to the report of the International Diabetes Federation (IDF), in 2017, the total number of diabetic patients aged 20-79 in the world has reached 415 million, and it is expected that by 2045, the number will increase to 629 million worldwide. Of those diagnosed, approximately 90% have type 2 diabetes. [0004] Insulin resistance, insufficient insulin secretion and increased endogenous glucose are the main causes of diabetes. [0005] Most current anti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/27A61K31/397A61K31/40A61K31/415A61K31/404A61K31/4035A61K31/403A61K31/416A61K31/4545A61K31/496A61K31/5377A61K31/4709A61K31/4725A61K31/427A61K31/433A61K31/381A61K31/4178A61K31/428A61K31/095A61K45/06A61K31/451A61K31/198A61K31/64A61K31/7036A61K31/133A61K31/4439A61K31/4985A61K31/155A61P3/10
CPCA61K31/095A61K31/133A61K31/155A61K31/198A61K31/27A61K31/381A61K31/397A61K31/40A61K31/403A61K31/4035A61K31/404A61K31/415A61K31/416A61K31/4178A61K31/427A61K31/428A61K31/433A61K31/4439A61K31/451A61K31/4545A61K31/4709A61K31/4725A61K31/496A61K31/4985A61K31/5377A61K31/64A61K31/7036A61K45/06A61P3/10A61K2300/00
Inventor 万坚李剑徐以香黄运远陈鑫任彦亮刘佳琪宋蓉蓉
Owner HUAZHONG NORMAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com